Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency, Chronic 1

Interventions

pembrolizumab 260Cyclophosphamide 244Specimen Handling 198fludarabine 175Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 122Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82fludarabine phosphate 79Gemcitabine 79Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Azacitidine 57Radiation 56Fluorouracil 56durvalumab 54Radiosurgery 53Temozolomide 48Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Quillaja Saponins × 1 year × Clear all
NCT06741072 2026-04-21

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
55 enrolled

Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡